cisplatin

Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy and quality-adjusted survival analysis
P.H.B. WILLEMSE, E.G.E. DE VRIES, M. KLOPPENBURG, D. L. FONTEIN, J. G. AALDERS, H. BOONSTRA

International Journal of Gynecologic Cancer Sep 1992, 2 (5) 236-243; DOI: 10.1046/j.1525-1438.1992.02050236.x
Low complication rate during intraperitoneal therapy through a totally implanted peritoneal access port in patients with ovarian cancer
A. G. NANNINGA, P.H.B. WILLEMSE, E.G.E. DE VRIES, H. BOONSTRA

International Journal of Gynecologic Cancer Mar 1992, 2 (2) 107-110; DOI: 10.1046/j.1525-1438.1992.02020107.x
Deregulation of miR-128 in Ovarian Cancer Promotes Cisplatin Resistance
Bing Li, Hong Chen, Nan Wu, Wen-Jing Zhang, Li-Xin Shang

International Journal of Gynecologic Cancer Oct 2014, 24 (8) 1381-1388; DOI: 10.1097/IGC.0000000000000252
A Randomized Comparison of Cisplatin and Oral Vinorelbine as Radiosensitizers in Aged or Comorbid Locally Advanced Cervical Cancer Patients
Jaime Alberto Coronel, Lucely del Carmen Cetina, David Cantú, Oscar Cerezo, Cintia Sánchez Hernández, Lesbia Rivera, Adela Poitevin Chacón, Alfonso Duenas-Gonzalez

International Journal of Gynecologic Cancer Jun 2013, 23 (5) 884-889; DOI: 10.1097/IGC.0b013e3182915c69
A Phase II Trial of Less Than 7 Weeks of Concomitant Cisplatin-Paclitaxel Chemoradiation in Locally Advanced Cervical Cancer
Rafael MartÍNez-Monge, Miren GaztaÑAga, José Manuel AramendÍA, Mauricio Cambeiro, Leire Arbea, Jaime EspinÓS, José Javier Aristu, Matías Jurado

International Journal of Gynecologic Cancer Jan 2010, 20 (1) 133-140; DOI: 10.1111/IGC.0b013e3181c057ff
Randomized Phase II Trial of Paclitaxel Plus Carboplatin Therapy Versus Irinotecan Plus Cisplatin Therapy as First-Line Chemotherapy for Clear Cell Adenocarcinoma of the Ovary: A JGOG Study
Satoshi Takakura, Masashi Takano, Fumiaki Takahashi, Toshiaki Saito, Daisuke Aoki, Noriyuki Inaba, Kiichiro Noda, Toru Sugiyama, Kazunori Ochiai, on behalf of the Japanese Gynecologic Oncology Group (JGOG)

International Journal of Gynecologic Cancer Feb 2010, 20 (2) 240-247; DOI: 10.1111/IGC.0b013e3181cafb47
Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer
A. Gadducci, M. Bruzzone, F. Carnino, N. Ragni, A. Rubagotti, P. F. Conte

International Journal of Gynecologic Cancer Jul 1996, 6 (4) 286-290; DOI: 10.1136/ijgc-00009577-199607000-00007
Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study
H. O. Smith, C. S. Jiang, G. R. Weiss, A. V. Hallum, P. Y. Liu, W. R. Robinson, P. C. Cheng, S. A. Scudder, M. Markman, D. S. Alberts

International Journal of Gynecologic Cancer Jan 2006, 16 (1) 298-305; DOI: 10.1136/ijgc-00009577-200601000-00048
Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer
M. Kanasugi, D. Aoki, N. Suzuki, N. Susumu, S. Nakata, M. Horiuchi, Y. Udagawa, S. Nozawa

International Journal of Gynecologic Cancer Jan 2006, 16 (1) 409-415; DOI: 10.1136/ijgc-00009577-200601000-00066
Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer
G. Bogliun, L. Marzorati, M. Marzola, M. D. Miceli, M. G. Cantù, G. Cavaletti

International Journal of Gynecologic Cancer Sep 1996, 6 (5) 415-419; DOI: 10.1136/ijgc-00009577-199609000-00012

Main menu

cisplatin

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

cisplatin

Pages